TAIPEI, Taiwan, April 18, 2013 /PRNewswire/ --
The presentation will be given at the 2013 Alzheimer's Disease International [ADI] Conference in Taipei, Taiwan
Professor Claude Wischik, Chairman of TauRx Therapeutics Ltd and pioneering researcher in tau pathology and Alzheimer's Disease, will be speaking at the 28th Conference of Alzheimer's Disease International. The global 3-day conference brings together more than 1,000 medical professionals, dementia experts, family carers, people living with dementia and national Alzheimer associations from more than 60 countries. This year's conference theme is aptly called 'Dementia: Action for Global Change.'
As a Silver Sponsor at this year's ADI conference, TauRx is affirming its corporate support and commitment to the Alzheimer's Disease International's call to action for global change in dementia - a commitment of significant importance in the wake of several failed clinical trials involving beta amyloid agents and a recent statement by yet another major pharmaceutical company halting its research in Alzheimer's.
Today at 14:45 pm, Professor Wischik will present details about the rationale for conducting tau-based therapeutic clinical research in China for Alzheimer's, and the economic and societal consequences of failing to do so.
Using demographic data from the World Health Organization, together with a proven cognitive staging system used to assess the severity of Alzheimer's based on the presence of tau tangles [tau pathology] in the brain, Professor Wischik will demonstrate why up to 155 million people in Asia will advance to moderate to severe Alzheimer's by 2050. Of major concern is the possibility that as many as one billion people will be at risk for earlier stages of Alzheimer's Disease.
TauRx Therapeutics recently launched Phase 3 clinical trials of its tau aggregation inhibitor, LMTX™, a compound which targets the formation of tau 'tangles' in the brain, and which aims to slow or halt the progression of Alzheimer's Disease in those with mild to moderate stages of the disease. Patients and carers can find further information at http://www.alzdirectory.org.
About TauRx Therapeutics:
TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's tau aggregation inhibitor, LMTX™, is currently in global Phase 3 clinical trials for Alzheimer's and Frontotemporal Dementia (FTD). LMTX™ targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to tangles. TauRx's primary research facilities are in Aberdeen, Scotland.
For press enquiries please contact:
SOURCE TauRx Therapeutics Ltd